Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6